{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:34:37Z","timestamp":1793198077581,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"American Society of Hematology\u2013Amos Medical Faculty Development Program","id":[{"id":"https:\/\/ror.org\/02nw48b86","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Birdies Fore Logan Foundation"},{"name":"Robert A. Winn Clinical Investigator Leadership"},{"name":"Blood Cancer United Specialized Center of Research","id":[{"id":"https:\/\/ror.org\/04m0xav37","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lymphoid malignancies consist of a heterogeneous group of diseases requiring diverse treatment approaches and outcomes. Therapeutic advances have been uneven across subtypes, and contemporary data on temporal changes in mortality remain limited. We assessed trends in survival and excess mortality using US population\u2013based data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included patients newly diagnosed with lymphoid malignancies during 2001 to 2018 from 17 registries of the Surveillance, Epidemiology, and End Results Program. We estimated 5-year relative survival and modeled excess mortality using Poisson regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five-year relative survival improved and excess mortality decreased over time for precursor lymphoid malignancies, Hodgkin lymphomas, and most mature B-cell lymphomas. Among subtypes with declining excess mortality, average reductions ranged from 6% to 20% per calendar period. The largest declines were observed for lymphocyte-rich Hodgkin lymphoma (20% reduction), followed by B-cell (19% reduction) and T-cell lymphoblastic leukemia\/lymphoma (18% reduction). In contrast, excess mortality for certain aggressive mature T-cell lymphomas showed little or no improvement, including adult T-cell leukemia\/lymphoma; peripheral T-cell lymphoma, not otherwise specified; and angioimmunoblastic T-cell lymphoma. Subgroup analyses suggested more pronounced excess mortality declines among younger adults compared with middle-aged or older adults for several subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Most lymphoid malignancies showed improvements in survival and declines in excess mortality over time. However, certain rare and aggressive subtypes exhibited limited or no progress. These findings may reflect overall benefits from advancements in treatment and supportive care while identifying research priorities for lymphoid subtypes with unmet survival needs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djag341","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:22:08Z","timestamp":1789755728000},"source":"Crossref","is-referenced-by-count":0,"title":["Temporal trends in relative survival and excess mortality among US adults with lymphoid malignancies"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3853-2603","authenticated-orcid":false,"given":"Bryan","family":"Valcarcel","sequence":"first","affiliation":[{"name":"Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Leautaud","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A T","family":"Hildebrandt","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alma","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"McCurry","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachet A","family":"Shukla","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethel","family":"Cesarman","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brady","family":"Beltran","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias de la Salud, Universidad San Ignacio de Loyola , Lima, Peru"},{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Hospital Nacional Edgardo Rebagliati Martins , Lima, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Qui\u00f1ones","sequence":"additional","affiliation":[{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Hospital Nacional Edgardo Rebagliati Martins , Lima, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisse","family":"Castro","sequence":"additional","affiliation":[{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Hospital Nacional Edgardo Rebagliati Martins , Lima, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Paredes","sequence":"additional","affiliation":[{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Hospital Nacional Edgardo Rebagliati Martins , Lima, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jule","family":"Vasquez","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Enfermedades Neoplasicas Medical Oncology Department, , Lima, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Barrionuevo","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Enfermedades Neoplasicas Medical Oncology Department, , Lima, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R","family":"Flowers","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7082-1846","authenticated-orcid":false,"given":"Luis","family":"Malpica","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026102810182605800_djag341-B1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"2026102810182605800_djag341-B2","doi-asserted-by":"publisher","first-page":"e70043","DOI":"10.3322\/caac.70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"2026102810182605800_djag341-B3","author":"Surveillance Research Program NCI"},{"key":"2026102810182605800_djag341-B4","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1200\/jco.2015.63.5540","article-title":"Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States","volume":"34","author":"Adams","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026102810182605800_djag341-B5","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1002\/cncr.33868","article-title":"Initial cancer treatment and survival in children, adolescents, and young adults with Hodgkin lymphoma: a population-based study","volume":"127","author":"Kahn","year":"2021","journal-title":"Cancer"},{"key":"2026102810182605800_djag341-B6","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1158\/1055-9965.Epi-20-0036","article-title":"Sex differences in cancer incidence and survival: a pan-cancer analysis","volume":"29","author":"Dong","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026102810182605800_djag341-B7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/bjh.15532","article-title":"Incidence and outcomes of lymphoid malignancies in adolescent and young adult patients in the United States","volume":"183","author":"Blum","year":"2018","journal-title":"Br J Haematol"},{"key":"2026102810182605800_djag341-B8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1200\/jco.23.01367","article-title":"Survival trends among adolescents and young adults diagnosed with cancer in the United States: comparisons with children and older adults","volume":"42","author":"Keegan","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026102810182605800_djag341-B9","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1080\/10428194.2019.1623886","article-title":"Temporal trends in treatment and survival of older adult diffuse large B-cell lymphoma patients in the SEER-Medicare linked database","volume":"60","author":"Shaw","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"2026102810182605800_djag341-B10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/cam4.655","article-title":"Improved survival time trends in Hodgkin\u2019s lymphoma","volume":"5","author":"Koshy","year":"2016","journal-title":"Cancer Med"},{"key":"2026102810182605800_djag341-B11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026102810182605800_djag341-B12","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/ijc.34163","article-title":"Global patterns of non-Hodgkin lymphoma in 2020","volume":"151","author":"Mafra","year":"2022","journal-title":"Int J Cancer"},{"key":"2026102810182605800_djag341-B13","doi-asserted-by":"publisher","first-page":"102044","DOI":"10.1016\/j.canep.2021.102044","article-title":"Disparities in the long-term survival of adolescent and young adult diffuse large B cell lymphoma survivors","volume":"75","author":"Berkman","year":"2021","journal-title":"Cancer Epidemiol"},{"key":"2026102810182605800_djag341-B14","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1002\/cncr.24548","article-title":"Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, 1981-2005","volume":"115","author":"Pulte","year":"2009","journal-title":"Cancer"},{"key":"2026102810182605800_djag341-B15","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s10552-015-0609-1","article-title":"US trends in survival disparities among adolescents and young adults with non-Hodgkin lymphoma","volume":"26","author":"Kent","year":"2015","journal-title":"Cancer Causes Control"},{"key":"2026102810182605800_djag341-B16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/s0140-6736(16)32407-2","article-title":"Non-Hodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"Lancet"},{"key":"2026102810182605800_djag341-B17","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1182\/blood-2008-09-180315","article-title":"HIV-associated lymphomas and gamma-herpesviruses","volume":"113","author":"Carbone","year":"2009","journal-title":"Blood"},{"key":"2026102810182605800_djag341-B18","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood.2020005469","article-title":"Hematologic cancers in individuals infected by HIV","volume":"139","author":"Carbone","year":"2022","journal-title":"Blood"},{"key":"2026102810182605800_djag341-B19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3324\/haematol.2014.107300","article-title":"Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989\u20132010","volume":"100","author":"Djamila","year":"2015","journal-title":"Haematologica"},{"key":"2026102810182605800_djag341-B20","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.clml.2015.06.005","article-title":"Persistent disparities among patients with T-cell non-Hodgkin lymphomas and B-cell diffuse large cell lymphomas over 40 years: a SEER database review","volume":"15","author":"Crozier","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026102810182605800_djag341-B21","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1182\/blood-2011-04-348367","article-title":"Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma","volume":"118","author":"Griffiths","year":"2011","journal-title":"Blood"},{"key":"2026102810182605800_djag341-B22","doi-asserted-by":"publisher","first-page":"6079","DOI":"10.1002\/cncr.27638","article-title":"Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma","volume":"118","author":"Griffiths","year":"2012","journal-title":"Cancer"},{"key":"2026102810182605800_djag341-B23","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"key":"2026102810182605800_djag341-B24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s12032-017-1001-7","article-title":"Improved survival in Medicare patients with multiple myeloma: findings from a large nationwide and population-based cohort","volume":"34","author":"Chen","year":"2017","journal-title":"Med Oncol"},{"key":"2026102810182605800_djag341-B25","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"2026102810182605800_djag341-B26","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D\u2019Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026102810182605800_djag341-B27","doi-asserted-by":"publisher","first-page":"a034843","DOI":"10.1101\/cshperspect.a034843","article-title":"Non-Hodgkin lymphomas: malignancies arising from mature B cells","volume":"11","author":"Shingleton","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026102810182605800_djag341-B28","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab\u2009+\u2009AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102810182605800_djag341-B29","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102810182605800_djag341-B30","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological aspects and world distribution of HTLV-1 infection","volume":"3","author":"Gessain","year":"2012","journal-title":"Front Microbiol"},{"key":"2026102810182605800_djag341-B31","doi-asserted-by":"publisher","first-page":"e258","DOI":"10.1016\/S2352-3026(25)00011-0","article-title":"Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study","volume":"12","author":"Malpica","year":"2025","journal-title":"Lancet Haematol"},{"key":"2026102810182605800_djag341-B32","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/jco.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026102810182605800_djag341-B33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026102810182605800_djag341-B34","doi-asserted-by":"publisher","first-page":"100002","DOI":"10.1016\/j.bglo.2025.100002","article-title":"Comparing the distribution of Hodgkin lymphoma subtypes and survival outcomes between Latin American and US patients","volume":"1","author":"Valcarcel","year":"2025","journal-title":"Blood Glob Hematol"},{"key":"2026102810182605800_djag341-B35","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3324\/haematol.2016.148809","article-title":"Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project","volume":"101","author":"Perry","year":"2016","journal-title":"Haematologica"},{"key":"2026102810182605800_djag341-B36","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1182\/blood-2017-04-778225","article-title":"Racial and ethnic disparities in hematologic malignancies","volume":"130","author":"Kirtane","year":"2017","journal-title":"Blood"},{"key":"2026102810182605800_djag341-B37","doi-asserted-by":"publisher","first-page":"6466","DOI":"10.1182\/bloodadvances.2023010690","article-title":"Disparities in survival of hematologic malignancies in the context of social determinants of health: a systematic review","volume":"7","author":"Miranda-Galvis","year":"2023","journal-title":"Blood Adv"},{"key":"2026102810182605800_djag341-B38","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/ajh.22078","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru","volume":"86","author":"Beltran","year":"2011","journal-title":"Am J Hematol"},{"key":"2026102810182605800_djag341-B39","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1002\/ajh.27430","article-title":"EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk-stratification, and management","volume":"99","author":"Malpica","year":"2024","journal-title":"Am J Hematology"},{"key":"2026102810182605800_djag341-B40","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag341\/71353934\/djag341.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag341\/71353934\/djag341.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:18:33Z","timestamp":1793197113000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article\/doi\/10.1093\/jnci\/djag341\/8832348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":40,"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag341","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"djag341"}}